Clinical Trial Detail

NCT ID NCT03850535
Title A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

acute myeloid leukemia

Therapies

Cytarabine + Idasanutlin

Cytarabine + Daunorubicin + Idasanutlin

Idasanutlin

Age Groups: adult senior

No variant requirements are available.